Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a ...

Key highlights include the DESTINY-Breast09 trial, which showed a significant improvement in progression-free survival with the combination of trastuzumab deruxtecan and pertuzumab in HER2 ...

Enhertu (fam-trastuzumab deruxtecan-nxki) followed by Taxol (paclitaxel), Herceptin (trastuzumab) and Perjeta (pertuzumab), also known as THP, showed a statistically significant and clinically ...

DESTINY-Breast09 special oral session will underscore potential of treating patients earlier with ENHERTU® (fam-trastuzumab deruxtecan-nxki) in HER2-positive metastatic breast cancer WILMINGTON ...

That’s certainly been my experience wearing Adidas’ new 3D-printed Climacool sneakers on the beach, trail, or in the city. I felt more eyes on my footwear than normal, with a determined flick ...

Among hospitalized patients with chronic liver disease, acute kidney injury and hepatorenal syndrome represent a growing clinical — and potential economic — burden, according to research ...